New strategies for Helicobacter pylori eradication

Current Opinion in Pharmacology

Volumn 8, Issue 5, 2008, Pages 593-597

  Selgrad, Michael ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH DERIVATIVE; CLARITHROMYCIN; CYTOCHROME P450 2C19; FINAFLOXACIN; HELICOBACTER PYLORI VACCINE; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL IMMUNITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION PREVENTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; STOMACH CANCER; TASTE DISORDER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; VACCINATION;

EID: 54849405120     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.04.010     Document Type: Review

References (52)

1. Fischbach L., and Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26 (2007) 343-357. Analysing the data from 93 studies with 10 178 participants, the authors demonstrate that drug resistance was a strong predictor of efficacy across triple therapies for the eradication of H. pylori in adults. Interestingly, the authors further show that resistance to either clarithromycin or metronidazole, but not both simultaneously, may be overcome by using quadruple therapies containing both clarithromycin and metronidazole.
2. Laine L., Fennerty M.B., Osato M., Sugg J., Suchower L., Probst P., and Levine J.G. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 95 (2000) 3393-3398
3. Treiber G., Malfertheiner P., and Klotz U. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 8 (2007) 329-350
4. Malfertheiner P., Megraud F., O'Morain C., Bell D., Bianchi P.G., Deltenre M., Forman D., Gasbarrini G., Jaup B., Misiewicz J.J., et al. Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 9 (1997) 1-2
5. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., el-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., and Kuipers E.J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
6. Ford A., and Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved?. Can J Gastroenterol 17 Suppl B (2003) 36B-40B
7. Zagari R.M., Bianchi-Porro G., Fiocca R., Gasbarrini G., Roda E., and Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 56 (2007) 475-479. Analysing 909 H. pylori-positive patients with duodenal ulcer, the authors showed that one-week and two-week triple treatments (containing both omeprazole, amoxicillin, clarithromycin) are similar in terms of efficacy, safety and patient compliance.
8. Megraud F., and Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 17 (2003) 1333-1343
9. McMahon B.J., Hennessy T.W., Bensler J.M., Bruden D.L., Parkinson A.J., Morris J.M., Reasonover A.L., Hurlburt D.A., Bruce M.G., Sacco F., and Butler J.C. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 139 (2003) 463-469
10. Katelaris P.H., Forbes G.M., Talley N.J., and Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 123 (2002) 1763-1769
11. Laine L., Hunt R., El-Zimaity H., Nguyen B., Osato M., and Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 98 (2003) 562-567
12. O'Morain C., Borody T., Farley A., De Boer W.A., Dallaire C., Schuman R., Piotrowski J., Fallone C.A., Tytgat G., Megraud F., and Spenard J. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 17 (2003) 415-420
13. Altintas E., Sezgin O., Ulu O., Aydin O., and Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 10 (2004) 1656-1658
14. Gumurdulu Y., Serin E., Ozer B., Kayaselcuk F., Ozsahin K., Cosar A.M., Gursoy M., Gur G., Yilmaz U., and Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 10 (2004) 668-671
15. Vakil N. Are there geographical and regional differences in Helicobacter pylori eradication?. Can J Gastroenterol 17 Suppl B (2003) 30B-32B
16. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53 (2004) 1374-1384
17. Toracchio S., and Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 35 (2003) 541-545
18. Fallone C.A. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 14 (2000) 879-882
19. Houben M.H., van de B.D., Hensen E.F., Craen A.J., Rauws E.A., and Tytgat G.N. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13 (1999) 1047-1055
20. Prazeres M.P., De Magalhaes Queiroz D.M., Campos Barbosa D.V., Aguiar R.G., Nogueira M.E., Santos A., Valle Correa P.R., Camargos Rocha A.M., Martins T.L., and ffonso de O.C. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 46 (2002) 2021-2023
21. Di Mario F., Cavallaro L.G., and Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. Dig Dis 24 (2006) 113-130
22. Perez A.L., Kato M., Nakagawa S., Kawarasaki M., Nagasako T., Mizushima T., Oda H., Kodaira J., Shimizu Y., Komatsu Y., et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 7 (2002) 306-309
23. Buckley M.J., Xia H.X., Hyde D.M., Keane C.T., and O'Morain C.A. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 42 (1997) 2111-2115
24. Pilotto A., Rassu M., Leandro G., Franceschi M., and Di M.F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 32 (2000) 763-768
25. Carothers J.J., Bruce M.G., Hennessy T.W., Bensler M., Morris J.M., Reasonover A.L., Hurlburt D.A., Parkinson A.J., Coleman J.M., and McMahon B.J. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 44 (2007) e5-e8
26. Thyagarajan S.P., Ray P., Das B.K., Ayyagari A., Khan A.A., Dharmalingam S., Rao U.A., Rajasambandam P., Ramathilagam B., Bhasin D., et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol 18 (2003) 1373-1378
27. Bruce M.G., Bruden D.L., McMahon B.J., Hennessy T.W., Reasonover A., Morris J., Hurlburt D.A., Peters H., Sacco F., Martinez P., et al. Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. Helicobacter 11 (2006) 581-588
28. Suzuki T., Matsuo K., Ito H., Sawaki A., Hirose K., Wakai K., Sato S., Nakamura T., Yamao K., Ueda R., and Tajima K. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 119 (2006) 217-224
29. Graham D.Y., Lew G.M., Malaty H.M., Evans D.G., Evans Jr. D.J., Klein P.D., Alpert L.C., and Genta R.M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102 (1992) 493-496
30. Katelaris P.H. Helicobacter pylori: why are eradication results so variable?. J Gastroenterol Hepatol 19 (2004) 606-609
31. Gisbert J.P., Hermida C., and Pajares J.M. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia?. Hepatogastroenterology 48 (2001) 1383-1388
32. Schwab M., Schaeffeler E., Klotz U., and Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 76 (2004) 201-209
33. Zullo A., Rinaldi V., Winn S., Meddi P., Lionetti R., Hassan C., Ripani C., Tomaselli G., and Attili A.F. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 14 (2000) 715-718
34. Zullo A., De F.V., Hassan C., Morini S., and Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 56 (2007) 1353-1357. The authors performed a pooled-data analysis of all studies on the sequential therapy regimen. More than 1800 patients have been treated with this regimen and eradication rates constantly higher than 90% at ITT analysis have been achieved. In this analysis the sequential regimen achieved higher eradication rates than standard triple therapies.
35. Vaira D., Zullo A., Vakil N., Gatta L., Ricci C., Perna F., Hassan C., Bernabucci V., Tampieri A., and Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 146 (2007) 556-563
36. Shehada S., Srugo I., and Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter 12 (2007) 645-647
37. Bishop A.J., Labischinski H., Stubbings W., and Buss A. Finafloxacin: a novel experimental fluoroquinolone with monotherapeutic potential for Helicoacter pylori eradication. Helicobacter 12 (2007) 424-435
38. Rupnow M.F., Shachter R.D., Owens D.K., and Parsonnet J. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 20 (2001) 879-885
39. Del G.G., Covacci A., Telford J.L., Montecucco C., and Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 19 (2001) 523-563
40. Marchetti M., Rossi M., Giannelli V., Giuliani M.M., Pizza M., Censini S., Covacci A., Massari P., Pagliaccia C., Manetti R., et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16 (1998) 33-37
41. Sutton P., Danon S.J., Walker M., Thompson L.J., Wilson J., Kosaka T., and Lee A. Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study. Gut 49 (2001) 467-473
42. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12 (2007) 89-102. This is a state-of-the-art review about the current status of H. pylori vaccine development.
43. Agarwal K., and Agarwal S. Helicobacter pylori vaccine: from past to future. Mayo Clin Proc 83 (2008) 169-175
44. Gatta L., Zullo A., Perna F., Ricci C., De F.V., Tampieri A., Bernabucci V., Cavina M., Hassan C., Ierardi E., et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 22 (2005) 45-49
45. Gisbert J.P., Castro-Fernandez M., Bermejo F., Perez-Aisa A., Ducons J., Fernandez-Bermejo M., Bory F., Cosme A., Benito L.M., Lopez-Rivas L., et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 101 (2006) 243-247
46. Zullo A., Hassan C., De F.V., Lorenzetti R., Marignani M., Angeletti S., Ierardi E., and Morini S. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 35 (2003) 232-236
47. Bilardi C., Dulbecco P., Zentilin P., Reglioni S., Iiritano E., Parodi A., Accornero L., Savarino E., Mansi C., Mamone M., et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2 (2004) 997-1002
48. Coelho L.G., Moretzsohn L.D., Vieira W.L., Gallo M.A., Passos M.C., Cindr J.M., Cerqueira M.C., Vitiello L., Ribeiro M.L., Mendonca S., et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 21 (2005) 783-787
49. Qasim A., Sebastian S., Thornton O., Dobson M., McLoughlin R., Buckley M., O'Connor H., and O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 21 (2005) 91-96
50. Perri F., Festa V., Clemente R., Quitadamo M., and Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 14 (2000) 311-316
51. Canducci F., Ojetti V., Pola P., Gasbarrini G., and Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 15 (2001) 143
52. Gisbert J.P., Calvet X., Bujanda L., Marcos S., Gisbert J.L., and Pajares J.M. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 8 (2003) 90-94